Inclusion Criteria:

- Ages eligible for this study are 18 years and older.

- Histological or cytological diagnosis of urothelial carcinoma. Mixed histologies are
permitted as long as transitional cell carcinoma is the major component (i.e. > 50%
of the pathologic specimen). Pure or predominant squamous cell carcinomas are not
permitted.

- Patients with transitional cell carcinomas of the renal pelvis and ureter are
permitted.

- Patients must have metastatic or locally advanced unresectable disease.

- Patients must have received one and only one prior chemotherapeutic regimen which
included platinum (at least one cycle) for metastatic/recurrent disease. Neoadjuvant
or adjuvant chemotherapy will be considered to have been first line if the patient
progressed within 12 months of the last dose.

- Patients with disease progression more than 12 months following platinum based
chemotherapy can be included (rather than platinum re-challenge), according to the
investigator's judgment.

- ECOG performance status ≤ 2

- Estimated life expectancy of > 12 weeks.

- Patients must have measurable disease according to RECIST1.1 criteria.

- If female of childbearing potential, pregnancy test is negative within 8 days priors
to first dose of study drug.

- If fertile, patient agrees to use an effective method of contraception to avoid
pregnancy for the duration of the study.

- Adequate organ function; Absolute neutrophil count ≥1.5 x 109/L. Platelet count ≥ 100
x109/L. Hemoglobin ≥ 9 g/dL. Total bilirubin ≤1.0x upper limit of normal. AST/SGOT
and/or ALT/SGPT ≤ 2.5x upper limit of normal. Calculated creatinine clearance > 40
ml/min (creatinine clearance will be calculated according to CKD-EPI formula:
http://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr).(27)

- Able to give informed consent.

Exclusion Criteria:

- Prior taxane therapy.

- Pregnant or lactating females

- Uncontrolled brain or leptomeningeal involvement (treated brain metastasis permitted
if both known lesions and medications e.g. steroids for that indication are stable).

- History of serious or concurrent illness that might be aggravated by study treatment.

- Known human immunodeficiency virus (HIV) infection or active hepatitis B/C.

- History of class II-IV congestive heart failure.

- Significant renal impairment.

- Uncontrolled hematuria.

- History of severe hypersensitivity reaction (≥grade 3) to docetaxel.

- History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing
drugs.

- Concurrent or planned treatment with strong inhibitors or strong inducers of
cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are
already on these treatments) (see Appendix).

- Other malignancies except adequately controlled basal cell carcinoma of the skin or
carcinoma in situ of the cervix or incidental prostate cancer (T1a, Gleason < 7 PSA <
10ng/ml) or any other tumor within 2 years prior to enrollment.

- Other investigational therapy or radiation therapy within 30 days before
registration.

- Patients not willing to employ adequate contraception for the duration of the study.